CN104394885B - 抗癌剂所致的末梢神经障碍性疼痛的预防和/或治疗剂 - Google Patents

抗癌剂所致的末梢神经障碍性疼痛的预防和/或治疗剂 Download PDF

Info

Publication number
CN104394885B
CN104394885B CN201380028318.4A CN201380028318A CN104394885B CN 104394885 B CN104394885 B CN 104394885B CN 201380028318 A CN201380028318 A CN 201380028318A CN 104394885 B CN104394885 B CN 104394885B
Authority
CN
China
Prior art keywords
thrombomodulin
administration
amino acid
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380028318.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104394885A (zh
Inventor
川畑笃史
铃木秀明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinki University Nishikawa
Asahi Kasei Pharma Corp
Original Assignee
Kinki University Nishikawa
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinki University Nishikawa, Asahi Kasei Pharma Corp filed Critical Kinki University Nishikawa
Publication of CN104394885A publication Critical patent/CN104394885A/zh
Application granted granted Critical
Publication of CN104394885B publication Critical patent/CN104394885B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380028318.4A 2012-05-31 2013-05-17 抗癌剂所致的末梢神经障碍性疼痛的预防和/或治疗剂 Active CN104394885B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31
JP2012-125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
CN104394885A CN104394885A (zh) 2015-03-04
CN104394885B true CN104394885B (zh) 2017-06-30

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028318.4A Active CN104394885B (zh) 2012-05-31 2013-05-17 抗癌剂所致的末梢神经障碍性疼痛的预防和/或治疗剂

Country Status (20)

Country Link
US (1) US10709767B2 (enExample)
EP (1) EP2857037B1 (enExample)
JP (3) JP6124417B2 (enExample)
KR (1) KR101672114B1 (enExample)
CN (1) CN104394885B (enExample)
AU (1) AU2013268725B2 (enExample)
BR (1) BR112014028852A2 (enExample)
CA (1) CA2875069C (enExample)
DK (1) DK2857037T3 (enExample)
ES (1) ES2743767T3 (enExample)
HU (1) HUE045997T2 (enExample)
IL (1) IL235984B (enExample)
IN (1) IN2014DN10075A (enExample)
MX (1) MX364934B (enExample)
NZ (1) NZ702242A (enExample)
PL (1) PL2857037T3 (enExample)
PT (1) PT2857037T (enExample)
RU (1) RU2595857C2 (enExample)
WO (1) WO2013179910A1 (enExample)
ZA (1) ZA201408769B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702242A (en) * 2012-05-31 2016-03-31 Asahi Kasei Pharma Corp Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
MX394717B (es) * 2017-03-31 2025-03-24 Toray Industries Agente terapeutico o profilactico para neuropatias perifericas.
EP3727367A4 (en) * 2017-12-19 2021-10-27 Synergia Life Sciences Pvt. Ltd VITAMIN K2 COMPOSITIONS FOR THE TREATMENT OF DRUG-INDUCED NEUROPATHY
AU2019347406B9 (en) * 2018-09-28 2023-11-16 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
US11497795B2 (en) * 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180496T1 (de) 1987-01-08 1999-06-15 Asahi Chemical Ind Peptid zur beschleunigung der wirkung des proteins-c mit thrombin
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
JP3189052B2 (ja) 1990-06-27 2001-07-16 持田製薬株式会社 抗血液凝固活性を有するポリペプチド
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
JP2716267B2 (ja) 1993-02-25 1998-02-18 アボツト・ラボラトリーズ 全血試料を高速溶解するための多目的試薬系
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
EP0763360B1 (en) 1994-04-20 2005-02-16 Asahi Kasei Pharma Corporation Use of thrombomodulin for treating liver injury
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
AU5304796A (en) 1995-03-06 1996-09-23 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
ES2242740T3 (es) 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
US20080280774A1 (en) * 2005-02-16 2008-11-13 Wyeth Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia
US8440832B2 (en) 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
KR20110008166A (ko) * 2008-02-18 2011-01-26 라보라토리오스 델 드라. 에스테브.에스.에이. 화학요법의 결과로 발생하는 신경병적 통증의 치료를 위한 시그마 수용체 리간드에 결합하는 화합물들의 용도
US20110144024A1 (en) * 2008-07-16 2011-06-16 Paion Deutschland Gmbh Prevention and treatment of radiation injury
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
NZ702242A (en) * 2012-05-31 2016-03-31 Asahi Kasei Pharma Corp Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TREATING PAIN FROM CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;ELLEN SMITH等;《NCL CANCER BULLETIN》;20101231;第7卷(第4期);第7页 *

Also Published As

Publication number Publication date
PL2857037T3 (pl) 2019-12-31
JP2018095652A (ja) 2018-06-21
HK1203846A1 (en) 2015-11-06
WO2013179910A1 (ja) 2013-12-05
AU2013268725A1 (en) 2014-12-18
CN104394885A (zh) 2015-03-04
ZA201408769B (en) 2015-12-23
AU2013268725B2 (en) 2017-02-16
NZ702242A (en) 2016-03-31
MX364934B (es) 2019-03-28
IL235984A0 (en) 2015-01-29
DK2857037T3 (da) 2019-07-22
KR20150004855A (ko) 2015-01-13
JP6124417B2 (ja) 2017-05-10
KR101672114B1 (ko) 2016-11-02
JP6427284B2 (ja) 2018-11-21
US20150148296A1 (en) 2015-05-28
BR112014028852A2 (pt) 2018-04-24
CA2875069C (en) 2018-01-02
JPWO2013179910A1 (ja) 2016-01-18
MX2014014505A (es) 2015-06-02
PT2857037T (pt) 2019-07-19
ES2743767T3 (es) 2020-02-20
HUE045997T2 (hu) 2020-01-28
RU2595857C2 (ru) 2016-08-27
EP2857037A1 (en) 2015-04-08
CA2875069A1 (en) 2013-12-05
RU2014148171A (ru) 2016-07-20
EP2857037A4 (en) 2016-04-06
IL235984B (en) 2019-09-26
US10709767B2 (en) 2020-07-14
IN2014DN10075A (enExample) 2015-08-21
EP2857037B1 (en) 2019-06-26
JP6279788B2 (ja) 2018-02-14
JP2017141268A (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
CN104394885B (zh) 抗癌剂所致的末梢神经障碍性疼痛的预防和/或治疗剂
JP2019535268A (ja) アクチビンＩＩａ型受容体変異体およびそれらの使用方法
KR20240051971A (ko) 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법
US20230241164A1 (en) C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer
CN108350035A (zh) 环状多肽、其获得方法和其在治疗中的应用
JP2011178687A (ja) 造血細胞移植に伴う疼痛の予防および／または治療剤
JP6815407B2 (ja) 副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
CN117679522A (zh) 用于防治神经系统病变的药物组合物及其应用
KR101377797B1 (ko) 미니-ＰＥＧ가 접합된 항-ｆｌｔ-1 펩타이드를 유효성분으로 함유하는 혈관신생 억제용 조성물
EA013565B1 (ru) Варианты полипептидов нейбластина, способы их получения и их применение
JP7245844B2 (ja) 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
HK1203846B (en) Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug
TW201609126A (zh) 利用胜肽來治療與血管新生相關之疾病
US11497795B2 (en) Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
HK40044828A (en) Medication for alleviating symptoms of peripheral neuropathy caused by anticancer drug and/or suppressing onset of peripheral neuropathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203846

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203846

Country of ref document: HK